99 related articles for article (PubMed ID: 20054018)
1. New data cheer champions of the danger theory.
Holzman DC
J Natl Cancer Inst; 2010 Jan; 102(2):76-8. PubMed ID: 20054018
[No Abstract] [Full Text] [Related]
2. [Regulation of antitumor immunity by controlling immune balance].
Wakita D; Nishimura T
Nihon Rinsho; 2005 Apr; 63 Suppl 4():555-61. PubMed ID: 15861710
[No Abstract] [Full Text] [Related]
3. Immunogenic cancer cell death: a key-lock paradigm.
Tesniere A; Apetoh L; Ghiringhelli F; Joza N; Panaretakis T; Kepp O; Schlemmer F; Zitvogel L; Kroemer G
Curr Opin Immunol; 2008 Oct; 20(5):504-11. PubMed ID: 18573340
[TBL] [Abstract][Full Text] [Related]
4. Ambient particulate matter directs nonclassic dendritic cell activation and a mixed TH1/TH2-like cytokine response by naive CD4+ T cells.
Williams MA; Porter M; Horton M; Guo J; Roman J; Williams D; Breysse P; Georas SN
J Allergy Clin Immunol; 2007 Feb; 119(2):488-97. PubMed ID: 17187851
[TBL] [Abstract][Full Text] [Related]
5. Do we have memory of danger as well as antigen?
Noble A
Trends Immunol; 2009 Apr; 30(4):150-6. PubMed ID: 19286426
[TBL] [Abstract][Full Text] [Related]
6. Immune system's Toll-like receptors have good opportunity for cancer treatment.
Schmidt C
J Natl Cancer Inst; 2006 May; 98(9):574-5. PubMed ID: 16670380
[No Abstract] [Full Text] [Related]
7. Optimal control in a model of dendritic cell transfection cancer immunotherapy.
Castiglione F; Piccoli B
Bull Math Biol; 2006 Feb; 68(2):255-74. PubMed ID: 16794930
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor signaling in anti-cancer immunity.
Okamoto M; Sato M
J Med Invest; 2003 Feb; 50(1-2):9-24. PubMed ID: 12630564
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell immunotherapy for the treatment of neoplastic disease.
Decker WK; Xing D; Shpall EJ
Biol Blood Marrow Transplant; 2006 Feb; 12(2):113-25. PubMed ID: 16443510
[TBL] [Abstract][Full Text] [Related]
10. The role of innate immunity in autoimmunity.
Bach JF; Bendelac A; Brenner MB; Cantor H; De Libero G; Kronenberg M; Lanier LL; Raulet DH; Shlomchik MJ; von Herrath MG
J Exp Med; 2004 Dec; 200(12):1527-31. PubMed ID: 15611284
[TBL] [Abstract][Full Text] [Related]
11. [Dendrite cell-based cancer vaccines--clinical application].
Svane IM; Berntsen A; Trepiakas R; Pedersen AE
Ugeskr Laeger; 2006 Apr; 168(14):1415-20. PubMed ID: 16584668
[TBL] [Abstract][Full Text] [Related]
12. Genetically modified dendritic cell-based cancer vaccines.
BubenÃk J
Folia Biol (Praha); 2001; 47(5):153-5. PubMed ID: 11686430
[No Abstract] [Full Text] [Related]
13. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination.
Kyte JA; Trachsel S; Risberg B; thor Straten P; Lislerud K; Gaudernack G
Cancer Immunol Immunother; 2009 Oct; 58(10):1609-26. PubMed ID: 19221745
[TBL] [Abstract][Full Text] [Related]
14. Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs.
Sun CM; Deriaud E; Leclerc C; Lo-Man R
Immunity; 2005 Apr; 22(4):467-77. PubMed ID: 15845451
[TBL] [Abstract][Full Text] [Related]
15. Polybacterial immunomodulator Respivax restores the inductive function of innate immunity in patients with recurrent respiratory infections.
Nikolova M; Stankulova D; Taskov H; Nenkov P; Maximov V; Petrunov B
Int Immunopharmacol; 2009 Apr; 9(4):425-32. PubMed ID: 19186221
[TBL] [Abstract][Full Text] [Related]
16. Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy.
Ueda Y; Itoh T; Fuji N; Harada S; Fujiki H; Shimizu K; Shiozaki A; Iwamoto A; Shimizu T; Mazda O; Kimura T; Sonoda Y; Taniwaki M; Yamagishi H
Cancer Immunol Immunother; 2007 Mar; 56(3):381-9. PubMed ID: 16830156
[TBL] [Abstract][Full Text] [Related]
17. Excitement tempered by long road ahead for dendritic cell vaccines.
Vanchieri C
J Natl Cancer Inst; 2004 Sep; 96(18):1350-1. PubMed ID: 15367563
[No Abstract] [Full Text] [Related]
18. Dendritic cells: a journey from laboratory to clinic.
Cerundolo V; Hermans IF; Salio M
Nat Immunol; 2004 Jan; 5(1):7-10. PubMed ID: 14699398
[No Abstract] [Full Text] [Related]
19. Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes.
Camporeale A; Boni A; Iezzi G; Degl'Innocenti E; Grioni M; Mondino A; Bellone M
Cancer Res; 2003 Jul; 63(13):3688-94. PubMed ID: 12839960
[TBL] [Abstract][Full Text] [Related]
20. Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines?
Sioud M
Scand J Immunol; 2009 Dec; 70(6):516-25. PubMed ID: 19906192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
